Aurobindo Pharma has reported results for the quarter ended June 30, 2011.
The Company has reported a net loss of Rs 101.58 crore for the quarter ended June 30, 2011 as compared to net profit of Rs 63.34 crore for the quarter ended June 30, 2010. The company’s total income registered growth of 18.77% at Rs 1031.87 crore for the June quarter of FY12 from Rs 868.81 crore for the June quarter of the previous Fiscal.
On Consolidated basis, the Group has reported a net loss of Rs 122.80 crore for the Q1FY12 as compared to net profit of Rs 51.50 crore for the quarter ended June 30, 2010. Its total income has increased by 16.69% at Rs 1079.79 crore for the quarter under review from Rs 925.36 crore for the quarter ended June 30, 2010.
Aurobindo Pharma headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1808.50 |
Dr. Reddys Lab | 1342.45 |
Cipla | 1472.45 |
Lupin | 2147.55 |
Zydus Lifesciences | 973.90 |
View more.. |